9 completed, 5 recruiting, 4 unknown, 2 terminated. 9 Phase 2, 6 Phase 3, 3 Not applicable, 3 Phase 1.
Follow Hypopharynx Cancer: new trials by email Literature Review of Hypopharynx Cancer trials Research Report on Hypopharynx Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population Celecoxib, Erlotinib Hydrochloride, Imaging Procedure - Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 25 | 2025-08-07 | 2026-10-01 |
| A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) Sacituzumab Govitecan, Cetuximab - Squamous Cell Carcinoma of Head and Neck, Sinus Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2025-07-02 | 2026-02-19 |
| Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma Vesanoid, Standard radiotherapy, Tailored radiotherapy - Oropharynx Cancer, Larynx Cancer | Phase 3 | Recruiting | Centre Leon Berard | 460 | 2025-02-20 | 2026-04-24 |
| SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx SBRT+Toripalimab Plus Docetaxel and Cisplatin - Laryngeal Cancer, Hypopharynx Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 35 | 2024-09-11 | 2024-09-26 |
| Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer chemotherapy TP regimen combined with Tislelizumab - Laryngeal Cancer, Hypopharynx Cancer | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 46 | 2024-08-01 | 2024-08-14 |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers Zimberelimab, Etrumadenant, Cisplatin - Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Withdrawn | Jennifer Choe | 2023-12-31 | 2023-11-30 | |
| The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors ENHANCE Intervention - Exercise and Nutrition, ENHANCE Intervention - Nutrition Only - Oral Cavity Cancer, Oropharynx Cancer | Not applicable | Completed | H. Lee Moffitt Cancer Center and Research Institute | 40 | 2023-04-06 | 2026-09-17 |
| Immunological Function After Radiation With Either Proton or Photon Therapy blood draws - HNSCC, Head and Neck Cancer | Unknown | University Medical Center Groningen | 40 | 2021-09-23 | 2023-08-30 | |
| Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy HNSCC, Oral Cavity Cancer | Recruiting | University Hospital Freiburg | 1500 | 2021-06-01 | 2025-03-25 | |
| Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma chemotherapy TP regimen combined with Toripalimab - Laryngeal Cancer, Hypopharynx Cancer | Phase 2 | Unknown | Fudan University | 42 | 2021-04-07 | 2022-01-18 |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Pembrolizumab, Cetuximab - HNSCC, Lip SCC | Phase 2 | Completed | University of California, San Diego | 78 | 2017-03-28 | 2026-10-01 |
| Adaptive Radiotherapy for Head and Neck Cancer Adaptive Radiotherapy - Head and Neck Cancer, Paranasal Sinus Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 64 | 2017-03-15 | 2021-10-26 |
| Cell-free Tumor DNA in Head and Neck Cancer Patients Liquid biopsy - Head and Neck Cancer, Head and Neck Neoplasms | Not applicable | Unknown | Christian von Buchwald | 500 | 2017-02-01 | 2021-09-21 |
| A Novel Modified Tracheo-Esophageal Voice Prosthesis for Total Laryngectomy Patients Modified Trans-Esophageal Prosthesis - Laryngeal Cancer, Hypopharynx Cancer | Not applicable | Unknown | HealthCare Global Enterprise Ltd. | 50 | 2016-04-18 | 2017-02-01 |
| Pembrolizumab in Combination With CRT for LA-SCCHN pembrolizumab (MK-3475), Cisplatin, Radiation - Head and Neck Cancer, Squamous Cell Carcinoma | Phase 1 | Completed | Sanford Health | 59 | 2015-11-01 | 2025-10-07 |
| Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer Homeodent®, 1.4% Sodium Bicarbonate solution - Oropharynx Cancer, Hypopharynx Cancer | Phase 3 | Terminated | Centre Leon Berard | 78 | 2009-05-01 | 2012-11-01 |
| Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation cetuximab, Cisplatin, Radiotherapy 70 Gy, 35 fractions - Larynx Cancer, Hypopharynx Cancer | Phase 2 | Completed | Groupe Oncologie Radiotherapie Tete et Cou | 156 | 2005-10-01 | 2011-06-27 |
| IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC IMRT 75 Gy, Conventional radiotherapy 70 Gy, concomitant cisplatin - Oral Cancer, Oropharynx Cancer | Phase 3 | Completed | Groupe Oncologie Radiotherapie Tete et Cou | 310 | 2005-09-27 | 2020-04-15 |
| Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma DOCETAXEL, Cisplatin, 5-Fluoro-3-Pyridinecarboxylic Acid - Larynx Cancer, Hypopharynx Cancer | Phase 3 | Completed | Groupe Oncologie Radiotherapie Tete et Cou | 220 | 2001-12-15 | 2019-02-15 |
| Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Conventional radiotherapy 70 Gy in 7 weeks, middle accelerated radiotherapy 70 Gy in 6 weeks, very accelerated radiotherapy 64.8 Gy in 3.5 weeks - Oral Cancer, Oropharynx Cancer | Phase 3 | Completed | Groupe Oncologie Radiotherapie Tete et Cou | 840 | 2000-03-01 | 2011-11-08 |
Showing 20 of 22. Sign in to see all of them.
Hypopharyngeal Neoplasms (22) · Laryngeal Neoplasms (20) · Oropharyngeal Neoplasms (16) · Mouth Neoplasms (12) · Head and Neck Neoplasms (9) · Squamous Cell Carcinoma of Head and Neck (8) · Nasopharyngeal Neoplasms (3) · Carcinoma, Squamous Cell (2) · Carcinoma (1) · Laryngeal Diseases (1) · Nasopharyngeal Carcinoma (1) · Neoplasm Metastasis (1) · Paranasal Sinus Neoplasms (1) · Pharyngeal Neoplasms (1) · Recurrence (1)
Neoplasms (22) · Neoplasms by Site (22) · Otorhinolaryngologic Diseases (22) · Otorhinolaryngologic Neoplasms (22) · Pharyngeal Diseases (22) · Stomatognathic Diseases (22) · Pharyngeal Neoplasms (21) · Respiratory Tract Diseases (20) · Respiratory Tract Neoplasms (20) · Laryngeal Diseases (19) · Head and Neck Neoplasms (13) · Mouth Diseases (13) · Neoplasms by Histologic Type (11) · Neoplasms, Glandular and Epithelial (11) · Carcinoma (10)
Cisplatin (7) · Cetuximab (4) · Docetaxel (2) · Fluorouracil (2) · Radiation (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · 5-fluoro-3-pyridinecarboxylic acid (1) · Blood Specimen Collection (1) · Carboplatin (1) · Celecoxib (1) · Erlotinib Hydrochloride (1) · Interviews as Topic (1) · Liquid Biopsy (1) · Methotrexate (1)
Groupe Oncologie Radiotherapie Tete et Cou (4) · Centre Leon Berard (2) · Memorial Sloan Kettering Cancer Center (2) · Christian von Buchwald (1) · Fudan University (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · HealthCare Global Enterprise Ltd. (1) · Henan Cancer Hospital (1) · Jennifer Choe (1) · Mayo Clinic (1) · Pharmacyclics LLC. (1) · Sanford Health (1) · Sun Yat-sen University (1) · University Hospital Freiburg (1)
United States (8) · France (7) · China (3) · Cyprus (1) · Czechia (1) · Denmark (1) · Germany (1) · India (1) · Netherlands (1) · Switzerland (1)
Jean Bourhis, PhD (2) · Assuntina Sacco, M.D. (1) · C. Jillian Tsai, MD (1) · Christian Von Buchwald, MD, DMSc (1) · Gilles Calais (1) · Gilles Calais, MD (1) · Jacques Tortochaux (1) · Jean Bourhis (1) · Jean-Louis Lefebvre (1) · Jennifer Choe, MD, PhD (1) · Katharine A. Price, MD (1) · Michel Lapeyre (1) · Michel Lapeyre, MD (1) · Nils H. Nicolay, MD, PhD (1)
PMID 21831465, PMID 23341517, PMID 32417348, PMID 32479189, PMID 33989559, PMID 40692081